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REVIEW
Antiangiogenic Agents in Combination with Chemotherapy in Patients
with Advanced Non-Small Cell Lung Cancer
Susanna V. Ulahannan and Julie R. Brahmer
DepartmentofOncology,SidneyKimmelComprehensiveCancerCenter,JohnsHopkinsUniversityHospital,Baltimore,
Maryland,USA
Mostpatientswithnon-smallcelllungcancer(NSCLC)present
withadvanceddiseaserequiringsystemicchemotherapy.
Treatmentwiththeantiangiogenicagentbevacizumabin
combinationwithstandardplatinum-baseddoublet
chemotherapyhasbeenshowntoimproveoutcomesin
patientswithadvancedNSCLC.Severalmultitargeted
antiangiogenictyrosinekinaseinhibitors(e.g.,sorafenib,
sunitinib,cediranib,vandetanib,BIBF1120,pazopanib,and
axitinib)arealsobeingevaluatedincombinationwithstandard
chemotherapy.Herewereviewcurrentclinicaldatawith
combinationtherapyinvolvingantiangiogenicagentsand
cytotoxicchemotherapyinpatientswithadvancedNSCLC.
Keywords: Antiangiogenesisinhibitors;Non-smallcelllung
cancer;Bevacizumab
INTRODUCTION
Lung cancer remains the leading cause of cancer-related
deaths in the United States, with approximately 219,440 new
cases and 159,390 deaths expected in 2009 (1). Each year
more deaths result from lung cancer than from breast, col-
orectal, and prostate cancers combined (2). Approximately
85% of all lung cancer cases are categorized as non-small cell
lung cancer (NSCLC), and most patients present with ad-
vanced disease at the time of diagnosis (1, 3). The standard
of care for patients with advanced disease is platinum-based
doublet chemotherapy (4). Adding a third cytotoxic agent
to the regimen increases toxicity and does not provide ad-
ditional clinical benefits (4). The Eastern Cooperative On-
c o l o g yG r o u p( E C O G )c o n d u c t e dal a r g e( N= 1,207) ran-
domized study that compared four platinum-based doublet
chemotherapy regimens in patients with NSCLC (5). None
of the regimens was found to yield superior efficacy, though
fewer episodes of toxicity were noted with the combination
of carboplatin and paclitaxel (5). The median survival in this
study was 8 months (5). Although there is a survival bene-
fit with improved quality of life when chemotherapy is given
to patients with advanced NSCLC, it appears that an efficacy
plateau is reached when conventional chemotherapy is used
alone.
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Angiogenesis is the growth of new microvessels from pre-
existing vasculature, a process that involves a fine balance
of proangiogenic and antiangiogenic factors and coordina-
tion between multiple cell types such as macrophages, en-
dothelialcells,andpericytes(6–9).Angiogenesisisnecessary
for cancer cells to proliferate beyond microscopic size and
to metastasize (10). The vasculature associated with patho-
l o g i ca n g i o g e n e s i si sa b n o r m a li ns t r u c t u r ea n df u n c t i o n ;i t
is characterized by tortuous, dilated, saccular vessels that are
poorly organized and hyperpermeable (6–8). These vascular
abnormalities lead to an abnormal tumor microenvironment
with interstitial hypertension, hypoxia, and acidosis; this, in
turn,increasestheproductionofvascularendothelialgrowth
f a c t o r( V E G F )a n dd e c r e a s e st h ee f f e c t i v e n e s so fc y t o t o x i c
chemotherapy (11, 12).
The vascular endothelial growth factor plays a key role in
regulation, both in normal and cancer cells, promoting en-
dothelial cell migration and proliferation necessary for an-
giogenesis. VEGF is over expressed in a majority of malig-
nant tumors, including NSCLC (12–15), and elevated blood
l e v e l so fV E G Fa r ea s s o c i a t e dw i t ht u m o ra g g r e s s i v e n e s sa n d
a poor prognosis (13). Three VEGF receptors (VEGFR) have
been identified: VEGFR1, VEGFR2, and VEGFR3. The bio-
logiceffectsofVEGFaremediatedbyVEGFR1andVEGFR2;
VEGFR2 is believed to play the primary role in activating
endothelial cells. VEGFR3 is associated primarily with lym-
phatic vessel growth (12, 14). Other growth factors, such as
platelet-derivedgrowthfactor(PDGF)andfibroblastgrowth
factor (FGF), also play key roles in promoting angiogenesis
(16, 17).
Bevacizumab is a monoclonal antibody that targets cir-
culating VEGF and inhibits VEGF binding to VEGFRs,
thereby preventing its proangiogenic activity (18). In 2006,
b e v a c i z u m a bw a sa p p r o v e db yt h eU SF o o da n dD r u gA d -
ministration for the first-line treatment of patients with
advanced nonsquamous NSCLC in combination with car-
boplatin and paclitaxel (19). However, resistance often de-
velops, and only approximately 50% of patients are actu-
ally eligible for bevacizumab treatment. Several mechanisms
have been proposed that may account for the additive or
synergistic activity of antiangiogenic agents and cytotoxic
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chemotherapy, including the possibility that anti-VEGF
therapy may transiently normalize leaky tumor vascula-
ture,whichcouldfacilita temoreeffectivedrugdeliverytothe
tumor (15). Although bevacizumab is currently the only ap-
proved antiangiogenic agent for patients with NSCLC, other
agents are in clinical development. These agents have been
evaluated in combinationwith a varietyof chemotherapeutic
drugs for the treatment of patients with NSCLC. In this re-
view ,wefocusontheuseofcombinationtherapywithantian-
giogenicagentsandchemotherapyinpatientswithadvanced
NSCLC.
TARGETING ANGIOGENESIS WITH BEVACIZUMAB
First-linetreatment
Bevacizumabisthefirstantiangiogenesisagenttoshowasur-
vival benefit when added to standard doublet chemotherapy
in the first-line treatment of patients with advanced NSCLC
( 2 0 ) .Ar a n d o m i z e dp h a s eI It r i a lo f9 9p a t i e n t sw i t ha d -
vanced NSCLC compared paclitaxel and carboplatin ther-
apy with or without bevacizumab 7.5 or 15 mg/kg (Table 1)
(21). The patients who received the higher dose of beva-
cizumab had a higher response rate (RR) (31.5% vs. 18.8%),
longer time to progression (TTP; 7.4 months vs. 4.2 months;
p =.023),andatrendtowardincreasedoverallsurvival(OS)
(17.7 months vs. 14.9 months; p = .63) compared with pa-
tientsgivenplacebo.However,fatalhemoptysiswasobserved
in four of 66 bevacizumab-treated patients and was appar-
ently associated with squamous cell histology, tumor cavita-
tion,centrallylocatedtumors,andtumorsclosetomajorves-
sels (21).
Subsequently, ECOG conducted a large, randomized,
multicenter, phase III study (E4599) that enrolled 878
patients with advanced or recurrent nonsquamous NSCLC
(Table 1) (20). Carboplatin/paclitaxel was administered
every 3 weeks for six cycles with or without bevacizumab
15 mg/kg (20). Treatment with bevacizumab was continued
until evidence of disease progression. In order to reduce the
risk of bleeding, patients with squamous cell histology, brain
metastases, therapeutic anticoagulation, or a history of gross
hemoptysis were excluded from the trial. The primary end
point, OS, was statistically superior in patients who received
bevacizumab (12.3 months vs. 10.3 months; hazard ratio
[HR], 0.79; p = .003) (20). These patients also showed a
significant improvement in RR (35% vs. 15%; p < .001) and
progression-free survival (PFS) (6.2 months vs. 4.5 months;
p < .001) (20). Increased frequencies of bleeding, febrile
neutropenia, hypertension, and proteinuria were reported
in the bevacizumab arm (p < .05). There was also a higher
incidence of treatment-related deaths in patients given
bevacizumab than in patients given chemotherapy alone
(15 vs. 2; p = .001) (20). The 15 deaths in the bevacizumab
a r mw e r ea t t r i b u t e dt op u l m o n a r yh e m o r r h a g e( N= 5),
complications of neutropenic fever (N = 5), gastrointestinal
(GI) bleeding (N = 2), cerebrovascular events (N = 2), and
ap r o b a b l ep u l m o n a r ye m b o l u s( N= 1) (20). Bevacizumab
was subsequently approved based on the results of this trial.
The retrospective analyses from E4599 revealed that OS
was not significantly improved with bevacizumab in women
( 2 0 ) .H o w e v e r ,O Sw i t ho rw i t h o u tb e v a c i z u m a bw a sh i g h e r
in women than in men, though this difference did not reach
statistical significance (20). There was no difference in OS in
patients of >70 years of age, but they did have a higher de-
gree of reported toxicity (38). The biomarkers VEGF, basic
FGF,intercellularadhesionmolecule(ICAM),andE-selectin
weremeasuredbeforeandaftertreatmentinE4599(39).Low
baseline ICAM levels were significantly associated with im-
proved RR (32% vs. 14% in patients with high ICAM levels;
p =.02)andOS(p =.00005)(39).Thissuggeststhatpatients
w i t hl o wb a s e l i n eI C A Ml e v e l sc o u l db e n e f i tf r o mt h ea d -
dition of bevacizumab to standard chemotherapy regimens;
however, this needs to be confirmed in prospective random-
ized trials.
A second phase III, randomized trial, AVAiL, evaluated
bevacizumab 7.5 mg/kg and 15 mg/kg in combination with
cisplatin and gemcitabine in patients with advanced non-
squamous NSCLC (Table 1) (33). This study showed signif-
i c a n ti m p r o v e m e n ti nt h ep r i m a r ye n dp o i n t ,P F S ,w i t ht h e
addition of bevacizumab at either the high dose (6.5 months
vs. 6.1 months; HR, 0.82; p = .03) or the low dose (6.7
months vs. 6.1 months; HR, 0.75; p = .003) compared with
chemotherapy alone, at a median follow-up of ≥7m o n t h s
( 3 3 ) .R e s p o n s er a t e si nt h ep a t i e n t sr e c e i v i n gh i g h - d o s eb e -
vacizumab, low-dose bevacizumab, and placebo were 30.4%
(p = .0023), 34.1% (p < .0001), and 20.1%, respectively (33).
After a median of ≥12.5 months of follow-up, median OS
wasnotsignificantlydifferentfromchemotherapyalonewith
bevacizumab 7.5 mg/kg (13.1 months vs. 13.6 months; HR,
0.93;p =.42)or15mg/kg(13.1monthsvs.13.4months;HR,
1.03; p = .761) (40). Although AVAiL trial was not powered
todirectlycomparethetwodosesofbevacizumab,theresults
indicate similar efficacy and toxicity profiles (33). A retro-
s pe ct i v ea n a l y s i sf o u n dt h a te i t h e rd o seo fbev a c i z u m a bu se d
assingle-agentmaintenancetherapymighthaveclinicalben-
efit (PFS, 4.6 months vs. 3.2 months with control), although
b e v a c i z u m a bw a sn o ta s s o c i a t e dw i t ha nO Sb e n e f i t( 4 1 ) .
Activity was also observed in a phase II study with the
combination of pemetrexed, carboplatin, and bevacizumab
followed by maintenance therapy with pemetrexed and be-
vacizumab as first-line treatment in patients with advanced
N S C L C( T a b l e1 )( 2 2 ) .I nt h e4 9p a t i e n t sa s s e s s e d ,R Rw a s
55%,PFSwas7.8months,andOSwas14.1months.Nograde
3/4 hypertension or pulmonary hemorrhage was observed,
b u tf o u rc a s e so fg r a d e3 / 4d i v e r t i c u l i t i sw e r er e p o r t e d( 2 2 ) .
This was a small trial that included more women than men,
which could explain the favorable survival rate. In light
o ft h ed a t af r o mt h i st r i a l ,t h el a r g e( N= 900) phase III
Pointbreak trial was initiated to compare (a) pemetrexed,
carboplatin,andbevacizumabfollowedbymaintenancether-
apy with pemetrexed and bevacizumab with (b) paclitaxel,
carboplatin, and bevacizumab followed by maintenance
bevacizumab(42).SeveralotherphaseIItrialsareevaluating
the combination of bevacizumab with platinum-based
doublet chemotherapy as first-line treatment in patients
with advanced NSCLC (Table 1) (22, 23–28, 30–32, 43). In
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Table 1. Results from phase II and III trials of bevacizumab in combination with chemotherapy as first-line or second-line NSCLC
treatment
Reference Phase Regimen Na RR (%) PFS (mo) OS (mo)
First-line
Johnson 2004 [21] II CBDCA AUC 6 + PTX 200 mg/m2 32 18.8 TTP,4.21 4 .9
CBDCA + PTX + Bev 7.5 mg/kg 32 28.1 TTP,4.31 1 .6
CBDCA + PTX + Bev 15 mg/kg 35 31.5 TTP,7.41 7 .7
Patel 2009 [22] II CBDCA AUC 6 + Pem 500 mg/m2 + Bev 15 mg/kg
with maintenance Pem 500 mg/m2 + Bev 15 mg/kg
49 55 7.81 4 .1
Skaff 2009 [23] II CBDCA AUC 6 + Pem 500 mg/m2 + Bev 15 mg/kg 25 36 TTP,7.25 ND
Dalsania 2007 [24] II CBDCA AUC 6 + Pem 500 mg/m2 + Bev 15 mg/kg 12 60 ND ND
Waples 2008 [25] II OX 120 mg/m2 + Pem 500 mg/m2 + Bev 15 mg/kg 58 26 7.81 6 .7
Wozniak 2009 [26] II Pem 500 mg/m2 + Gem 1500 mg/m2 + Bev 10 mg/kg
every 2 weeks
18 61 ND ND
Lilenbaum 2008 [27] II OX 130 mg/m2 + Gem 1,000 mg/m2 + Bev 15 mg/kg 44 43 ND 13.7
Leon 2009 [28] II CDDP 80 mg/m2 + Vinorelbine 25 mg/m2 + Bev 15
mg/kg
17 29.44 .6N D
Herbst 2007 [29] II TXT 75 mg/m2 or Pem 500 mg/m2 + Bev 15 mg/kg 40 12.54 .81 2 .6
TXT 75 mg/m2 or Pem 500 mg/m2 + placebo 41 12.23 .08 .6
Bev 15 mg/kg + Erlotinib 150 mg/day 39 17.94 .41 3 .7
Ferrer 2009 [30] II CDDP 75 mg/m2 + TXT 75 mg/m2 + Bev 15 mg/kg 46 63 7.81 3 .5
William 2010 [30] II CBDCA AUC 6 + TXT 75 mg/m2 + Bev 15 mg/kg 40 52.57 .91 6 .5
Reynolds 2009 [31] II nabPTX 300 mg/m2 CBDCA AUC 6 + Bev 15 mg/kg 50 31 9.81 6 .8
Clement-Duchene 2010 [32] II CBDCA AUC 5 + Gem 1000 mg/m2 + Bev 15 mg/kg 47 14.98 .71 2 .8
Sandler 2006 [20] III CBDCA AUC 6 + PTX 200 mg/m2 433 15 4.51 0 .3
CBDCA + PTX + Bev 15 mg/kg 417 35 6.21 2 .3
Reck 2009 [33] III CDDP 80 mg/m2 + Gem 1,250 mg/m2 327 20.16 .1N R
CDDP + Gem + Bev 7.5 mg/kg 330 34.16 .7N R
CDDP + Gem + Bev 15 mg/kg 329 30.46 .5N R
Crino 2010 [34] III Chemotherapy + Bev 7.5 or 15 mg/kg 2,212 51.0 TTP,7.81 4 .6
Fischbach 2009 [35] III Chemotherapy + Bev 7.5 or 15 mg/kg 1,758 ND 6.7N D
Second-line
Adjei 2010 [36] II Pem 500 mg/m2 + Bev 15 mg/kg 48 10 4.08 .6
Heist 2008 [37] II Pem 500 mg/m2 + OX 120 mg/m2 + Bev 15 mg/kg 34 27 5.81 2 .5
aPatients evaluable for efficacy.
Abbreviations.A U C :a r eau n d e rth ecu rv e ;Bev:bev a c i z u m a b ;C B DC A :ca rbo p l a ti n ;C D D P :c i s p l a ti n ,E F S :ev e n t - fr ees u rvi v al ;Ge m :g e m c i ta b i n e ;N D :n od a taa v a il a b le; NSCLC:
n o n - s m a l lc e l ll u n gc a n c e r ;O S :o v e r a l ls u r v i v a l ;O X :o x a l i p l a t i n ;P e m :p e m e t r e x e d ;P F S :p r o g r e s s i o n - f r e es u r v i v a l ;P T X :p a c l i t a x e l ;R R :r e s p o n s er a t e ;T T P :t i m et op r o g r e s s i o n ;
TXT: docetaxel.
addition, many other clinical studies are currently recruiting
p a t i e n t sa n dw i l le v a l u a t ef i r s t - l i n eb e v a c i z u m a bi nc o m b i -
nation with chemotherapy and/or pemetrexed (Table 2).
Second-lineTreatment
Bevacizumab has also been studied as second-line therapy
( T a b l e1 ) .O n ep h a s eI It r i a le v a l u a t e dt h ee f f i c a c ya n dt o x i -
city of pemetrexed plus bevacizumab as second-line therapy
in48patientswithadvancedNSCLC(36).Apartialresponse
(PR) was reported in five patients (10%) and stable disease
(SD) was reported in 19 patients (40%), with a median PFS
of 4.0 months and OS of 8.6 months (36). The grade 3/4
hematologic toxicities occurring in ≥10% of patients were
neutropenia (19%), leukopenia (17%), and lymphopenia
(13%) (36). The grade 3/4 nonhematologic toxicities occur-
ring in ≥10% of patients were thrombosis (10%), dyspnea
(10%), and fatigue (13%) (36). A separate phase II trial
compared bevacizumab plus chemotherapy (docetaxel or
pemetrexed),bevacizumabpluserlotinib,andchemotherapy
alone in 120 patients with advanced nonsquamous NSCLC
in the second-line treatment setting (29). Median PFS for
bevacizumab–chemotherapy, bevacizumab–erlotinib, and
chemotherapy alone was 4.8 months, 4.4 months, and 3.0
months, respectively, while median OS was 12.6 months,
13.7 months, and 8.6 months, respectively. There were no
significant differences for these outcomes between the two
bevacizumab arms, but superiority for disease progression
or death was demonstrated for bevacizumab–chemotherapy
versus chemotherapy alone (HR, 0.66, 95% CI, 0.38–1.16)
and for bevacizumab–erlotinib versus chemotherapy alone
(HR, 0.72, 95% CI, 0.42–1.23). Partial response or complete
response (CR) was reported in five patients in each of the
bevacizumab–chemotherapy and chemotherapy alone arms,
a n df o rs e v e np a t i e n t si nt h eb e v a c i z u m a b – e r l o t i n i ba r m
(29). The grade 3/4 neutropenia occurred in eight patients
receiving bevacizumab–chemotherapy, two patients receiv-
ing bevacizumab–erlotinib, and seven patients receiving
chemotherapy alone.
These results and those of an earlier randomizedphase III
trial comparing pemetrexed and docetaxel suggest that the
combination of bevacizumab and pemetrexed may provide
clinicalbenefitinthetreatmentofNSCLC(44).Resultsfrom
anotherphaseIIstudysuggestthattheadditionofoxaliplatin
to bevacizumab/pemetrexed may further improve outcomes
(Table 1) (37).
Safety
The toxicities associated with bevacizumab may be directly
r e l a t e dt oi t sm e c h a n i s mo fa c t i o n .H y p e r t e n s i o n ,w h i c h
o c c u r sf r e q u e n t l y ,m a yb ed u et ot h ed e c r e a s e ds y n t h e s i s
Copyright C   2011 Informa Healthcare USA, Inc. S. V. Ulahannan and J. R. Brahmer
Table 2. Overview of ongoing (actively recruiting) phase II and III trials of bevacizumab in NSCLCa
Phase Trial description
Identifier
number
Early-stage NSCLC
II Neoadjuvant bevacizumab in combination with cisplatin-based chemotherapy versus neoadjuvant cisplatin and
docetaxel, both followed by adjuvant bevacizumab, in patients with Stage IB–IIIA NSCLC undergoing surgical
resection.
NCT00130780
II Neoadjuvant bevacizumab in combination with carboplatin and paclitaxel in patients with Stage IB−IIA NSCLC
undergoing surgical resection.
NCT00960297
II Neoadjuvant bevacizumab in combination with cisplatin and gemcitabine, followed by cisplatin and etoposide after
surgical resection, in patients with Stage IIIA NSCLC.
NCT00924209
II Adjuvant bevacizumab in combination with carboplatin and docetaxel, followed by maintenance bevacizumab and
erlotinib, in patients with surgically resected Stage IB−IIIA NSCLC.
NCT00621049
III Adjuvant bevacizumab in combination with chemotherapy versus chemotherapy alone in patients with surgically
resected Stage IB−IIIA NSCLC.
NCT00324805
First-line in advanced NSCLC
II Bevacizumab in combination with carboplatin and gemcitabine. NCT00150657
II Bevacizumab in combination with carboplatin and gemcitabine. NCT00400803
II Bevacizumab in combination with carboplatin and abraxane. NCT00642759
II Bevacizumab in combination with carboplatin, paclitaxel, and erlotinib. NCT00550537
II Bevacizumab in combination with carboplatin, paclitaxel, and imprime PGG R   injection. NCT00874107
II Bevacizumab in combination with paclitaxel and gemcitabine. NCT00655850
II Bevacizumab in combination with docetaxel in patients aged >75 years. NCT00541099
II Bevacizumab in combination with gemcitabine and cisplatin versus bevacizumab in combination with gemcitabine in
patients aged ≥70 years.
NCT01077713
II Bevacizumab in combination with platinum-based chemotherapy versus bevacizumab in combination with erlotinib. NCT00531960
II Bevacizumab in combination with carboplatin and paclitaxel versus bevacizumab in combination with carboplatin,
paclitaxel, and erlotinib in nonsmokers.
NCT00976677
II Bevacizumab in combination with carboplatin and paclitaxel versus bevacizumab in combination with carboplatin,
paclitaxel, and cixutumumab.
NCT00955305
II Bevacizumab in combination with carboplatin and paclitaxel, versus CT-322 in combination with carboplatin and
paclitaxel.
NCT00850577
II Bevacizumab in combination with carboplatin and paclitaxel, or second-line bevacizumab in combination with
erlotinib, in patients with asymptomatic untreated brain metastases.
NCT00800202
II Bevacizumab in combination with pemetrexed. NCT00254319
II Bevacizumab in combination with paclitaxel and pemetrexed. NCT00807573
II Bevacizumab in combination with carboplatin and pemetrexed. NCT00614822
II Bevacizumab in combination with carboplatin and pemetrexed in patients with ECOG performance status 2. NCT00892710
II Bevacizumab in combination with cisplatin and pemetrexed. NCT00998166
II Bevacizumab in combination with gemcitabine and pemetrexed. NCT00438204
II Bevacizumab in combination with erlotinib in patients aged ≥70 years. NCT00553800
II Bevacizumab in combination with cisplatin and pemetrexed versus bevacizumab in combination with erlotinib. NCT01116219
II Bevacizumab in combination with cisplatin and pemetrexed, followed by maintenance bevacizumab and pemetrexed. NCT01004250
II Bevacizumab in combination with carboplatin and gemcitabine, followed by bevacizumab in combination with erlotinib
at disease progression.
NCT00702975
II Bevacizumab in combination with carboplatin and docetaxel, followed by second-line bevacizumab and pemetrexed or
second-line pemetrexed alone.
NCT00766246
III Carboplatin and paclitaxel with or without bevacizumab versus carboplatin, paclitaxel, and cetuximab with or without
bevacizumab.
NCT00946712
III Bevacizumab in combination with pemetrexed, versus bevacizumab alone and pemetrexed alone. NCT01107626
III Bevacizumab in combination with pemetrexed and carboplatin versus bevacizumab in combination with pemetrexed in
patients aged >65 years.
NCT00976456
III Bevacizumab in combination with cisplatin and pemetrexed, followed by maintenance bevacizumab and pemetrexed,
versus maintenance bevacizumab alone.
NCT00961415
III Bevacizumab in combination with carboplatin and pemetrexed, followed by maintenance bevacizumab and pemetrexed,
versus first-line bevacizumab in combination with carboplatin and paclitaxel, followed by maintenance bevacizumab.
NCT00762034
III Bevacizumab in combination with carboplatin and paclitaxel, followed by maintenance bevacizumab, versus first-line
pemetrexed in combination with carboplatin, followed by maintenance pemetrexed.
NCT00948675
Second- or third-line in advanced NSCLC
II Second- or third-line bevacizumab in combination with carboplatin and paclitaxel. NCT00753909
II Second-line bevacizumab in combination with vinorelbine. NCT00755170
II Second-line bevacizumab in combination with docetaxel. NCT00741195
II Second-line bevacizumab in combination with pemetrexed. NCT00741221
II Second-line bevacizumab in combination with pemetrexed versus pemetrexed alone. NCT00735891
II Second-line bevacizumab in combination with erlotinib. NCT00749567
II Second-line bevacizumab in combination with erlotinib. NCT00436332
II Second-line bevacizumab in combination with ixabepilone. NCT01057212
aClinicalTrials.gov accessed on November 22, 2010.
Abbreviations. ECOG: Eastern Cooperative Oncology Group; NSCLC: non-small cell lung cancer.
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of nitrous oxide that occurs as a result of VEGF inhibition
and leads to increased vascular tone (45). In addition,
hypertension induced by bevacizumab may also contribute
to proteinuria (46).
Bevacizumab has been associated with a large number
of potentially serious adverse events (AEs) in patients with
NSCLC. The most serious, and sometimes fatal, are GI per-
foration, wound healing complications, hemorrhage, arterial
thromboembolic events, hypertension, nephrotic syndrome,
neutropenia,andcongestiveheartfailure(47).CommonAEs
in patients receiving bevacizumab include asthenia, abdom-
inal pain, other pain, headache, hypertension, diarrhea, nau-
sea, vomiting, anorexia, stomatitis, constipation, upper res-
piratory infection, epistaxis, dyspnea, exfoliative dermatitis,
and proteinuria (47).
The ATLAS trial of maintenance bevacizumab and er-
lotinib (N = 598) (48), the PASSPORT trial of bevacizumab
with first- or second-line chemotherapy (N = 106) (49),
and the BeTa trial of bevacizumab with erlotinib in the
second-line setting (N = 37) (50) all included patients with
treatedbrainmetastases,withsomereceivingtherapeutican-
ticoagulation. Central nervous system (CNS) hemorrhages
were reported in three patients participating in ATLAS, and
five patients in ATLAS and three patients in PASSPORT-
experiencedpulmonaryhemorrhages(48,49).Thesedatain-
dicatethatpatientswithtreatedbrainmetastasesandpatients
receivingtherapeuticanticoagulationmaybetreatedwithbe-
vacizumab.
The most common AEs in AVAiL were hematologic and
related to GI, with a similar incidence in the three treatment
arms (low-dose bevacizumab, high-dose bevacizumab, and
placebo) (51). Adverse events that occurred at a higher fre-
quency with bevacizumab included hypertension (7% and
9%vs.2%),proteinuria(2%and3%vs.0%),andbleeding(4%
and 5% vs. 2%). Hemoptysis was reported in 0.5% and 1.2%
of patients in the low- and high-dose bevacizumab arms and
in1.3%ofpatientsintheplaceboarm(51).SeriousAEswere
reported in 39%, 45%, and 36% of patients, respectively (51).
Despite the fact that 9% of the study population was receiv-
ing therapeutic anticoagulation, no pulmonary hemorrhage
was reported in the initial publication of the trial or the final
safety analysis (33, 51).
Two large cohort studies (SAiL and ARIES) have focused
on the safety of bevacizumab. SAiL, which enrolled 2,212
p a t i e n t s ,e v a l u a t e dt h es a f e t yo ff i r s t - l i n eb e v a c i z u m a b ,7 . 5
mg/kg and 15 mg/kg, in combination with chemotherapy.
At baseline, 4% ofthe patientsreceivedanticoagulationther-
apy,withbleedingseenin924patients(34).However,signifi-
cant bleeding and hemoptysis were rare and serious bleeding
(grade ≥3) of any cause was reported in 81 patients. Arte-
rial and venous thromboembolism occurred in 302 patients,
and cerebral hemorrhage in seven patients (34). Congestive
heart failure was observed in 17 patients. Hypertension oc-
curred in 790 patients, but only 125 patients had grade ≥3
hypertension. Proteinuria was reported in 764 patients, and
GI perforation was reported in 30 patients (34).
The ARIES trial (N = 1,518), which is evaluating be-
vacizumab in combination with first-line chemotherapy
regimens, has enrolled patients with locally advanced
or metastatic NSCLC. The most common first-line
chemotherapeutic regimen used with bevacizumab was
carboplatin/paclitaxel (64%) (35). Of the treated patients,
8% had brain metastases and 5% were receiving therapeutic
anticoagulation. A total of 45 patients had a grade ≥3 bleed-
ing event, one had CNS hemorrhage, and 22 had serious
arterial thromboembolic events. Adverse effects in the
overall population included hypertension (3.8%) and grade
≥3bleedingevents(GIhemorrhage,1.1%;severepulmonary
hemorrhage, 0.7%; and CNS hemorrhage, 0.1%) (35).
Results from E4599 have suggested a longer OS in pa-
tients with hypertension (15.9 months vs. 11.5 months with-
out hypertension) and improved PFS with the onset of hy-
pertension during bevacizumab treatment (7.0 months vs.
5.5 months), although these results did not reach statisti-
cal significance (52). Similar findings regarding the relation-
ship between bevacizumab-associated hypertension and im-
proved survival have been reported in the CALGB 90206
trial involving patients with metastatic renal cell carcinoma
(53).However,furtherinvestigationofthisassociationiswar-
ranted. A recent presentation of a large study of approxi-
mately 5,900 patients across six placebo-controlled, phase III
studies of bevacizumab showed hypertension arising during
treatment did not predict improvement in PFS or OS (54).
A retrospective evaluation of risk factors associated with
severe pulmonary hemorrhage in patients treated with car-
boplatin/paclitaxel plus bevacizumab suggests that baseline
tumor cavitation was the only risk factor for early-onset pul-
monaryhemorrhage.Centraltumorlocationwasnotpredic-
tive of risk (55).
SMALL-MOLECULE, ANTIANGIOGENIC TYROSINE
KINASE INHIBITORS (TKIs)
The proangiogenic activity of VEGF is dependent on signal-
i n gt h r o u g hi t sc o g n a t er e c e p t o r s( i . e . ,t h eV E G F R s ) ;t h u s ,
blocking these receptors is another antiangiogenic strategy
(56). The receptors can be inhibited using small-molecule
TKIs, which compete with adenosine triphosphate(ATP) for
the active site of the tyrosine kinase (TK) domain and block
receptor activation (56). Many TKIs that inhibit VEGFR also
inhibit other key pathways involved in angiogenesis, includ-
ing FGF and PDGF and their respective receptors (56). It has
been suggested that because of some redundancy in proan-
giogenic signaling, both the FGF and PDGF pathways may
playaroleinthedevelopmentofresistancetoVEGFblockade
(57–60). Thus, by targeting multiple pathways, these agents
m a yh a v et h ep o t e n t i a lt oo v e r c o m er e s i s t a n c et oa g e n t sd i -
rected against only VEGF, such as bevacizumab (61, 62).
Sorafenib
Sorafenib is an oral multi-kinase inhibitor that targets tumor
growth, survival, and angiogenesis, by inhibiting VEGFR2,
VEGFR3,andPDGFreceptor(PDGFR)TKs(63).Italsotar-
gets the Raf kinases, key signaling molecules downstream of
Ras that transmit proliferative and cell survival signals (63).
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Table 3. Results from phase II and III trials of antiangiogenic TKIs in combination with chemotherapy in NSCLC
Reference Phase Regimen Na RR (%) PFS (mo)
OS
(mo)
Sorafenib
Flaherty 2008 (66) I CBDCA AUC 6 + PTX 225 mg/m2 + sorafenib
100, 200, or 400 mg twice daily.
39 26 10.1 (melanoma) NR
3.4 (other tumor types)
Scagliotti 2010 (67) III CBDCA AUC 6 + PTX 225 mg/m2 + placebo. 462 24 5.4 10.6
CBDCA AUC 6 + PTX 225 mg/m2 + sorafenib 400
mg twice daily.
464 27.4 4.6 10.7
Cediranib
Gadgeel 2009 (68) II Pem 500 mg/m2 + cediranib 30 mg/day. 31 16 NR NR
Vandetanib
De Boer 2009 (69) I Pem 500 mg/m2 + vandetanib 100 mg/day. 10 10 NR NR
Pem 500 mg/m2 + vandetanib 300 mg/day. 11 0 NR NR
Heymach 2008 (70) II CBDCA AUC 6 + PTX 200 mg/m2 + placebo. 52 25 ∼6 (23 weeks) 12.6
CBDCA AUC 6 + PTX 200 mg/m2 + vandetanib
300 mg/day.
56 32 ∼6 (24 weeks) 10.2
Heymach 2007 (71) II TXT 75 mg/m2 + placebo. 41 12 2.8 13.4
TXT 75 mg/m2 + vandetanib 100 mg/day. 42 26 4.3 13.1
TXT 75 mg/m2 + vandetanib 300 mg/day. 44 18 4.0 7.9
Herbst 2010 (72) III TXT 75 mg/m2 + placebo. 697 10 3.2 9.9
TXT 75 mg/m2 + vandetanib 100 mg/day. 694 17 4.0 10.3
De Boer 2009 (73) III Pem 500 mg/m2 + placebo. 278 7.9 NR NR
Pem 500 mg/m2 + vandetanib 100 mg/day. 256 19.1 NR NR
aPatients evaluable for efficacy.
Abbreviations. AUC: area under the curve; CBDCA: carboplatin; NR: not reported; NSCLC: non-small cell lung cancer; OS: overall survival; Pem: pemetrexed; PFS: progression-
free survival; PTX: paclitaxel; RR: response rate; TKI: tyrosine kinase inhibitor; TXT: docetaxel.
Single-agentsorafenibhasshownactivityinpatientswithad-
vanced NSCLC in the first-line setting (64, 68).
Sorafenib has been combined with conventional
chemotherapy in multiple studies (Table 3) (66, 67). In
one phase I/II trial, carboplatin/paclitaxel in combination
with sorafenib was evaluated in patients with advanced
NSCLC (66). Among 39 evaluable patients, nine achieved
aP R ,a n do n ea c h i e v e daC R ;h o w e v e r ,a l lt h e s ep a t i e n t s
had melanoma. Median PFS for patients without melanoma
was 104 days. The drug-related AEs were similar to those
reported with single-agent sorafenib and included rash,
hand–foot syndrome, and GI side effects (66, 74). Based
on these results, the randomized phase III ESCAPE trial
was initiated. The ESCAPE trial enrolled 926 patients with
advanced NSCLC who received carboplatin/paclitaxel with
or without sorafenib as first-line therapy (67). There were
no significant differences between the treatment arms in RR
(24% vs. 27%), PFS (4.6 months vs. 5.4 months), or OS (10.7
monthsvs.10.6months),andasaresultthetrialwasstopped
e a r l y .T h e r ew a sah i g h e rr a t eo fd r u g - r e l a t e di n f e c t i o ni n
patients who received sorafenib than in those who received
placebo (6.5% vs. 2.2%; p = .002). The grade 5 toxicity was
observed more frequently in patients who received sorafenib
versus those who received chemotherapy alone (14 patients
vs. 4 patients; p < .001). In a subset analysis, shorter survival
timeswereobservedinpatientswithsquamouscellhistology
who received sorafenib plus chemotherapy compared with
those who received chemotherapy alone, though this obser-
vation was not statistically significant (67). Another ongoing
large phase III trial, NExUS (NCT00449033), is evaluating
gemcitabine/cisplatin with or without sorafenib as first-line
therapy in patients with NSCLC (Table 3), and other studies
are assessing second-line sorafenib monotherapy (Table 4).
Sunitinib
Sunitinib is a multitargeted small-molecule TKI that tar-
gets VEGFR1, VEGFR2, VEGFR3, PDGFR, fms-like TK-3
(Flt3), c-kit, and rearranged during transfection (RET) (75,
76). Sunitinib has shown single-agent activity in a multi-
center phase II trial as second- or third-line therapy in pa-
tients with advanced NSCLC, when administered accord-
ing to a schedule of 4 weeks with treatment followed by 2
weeks without treatment, at a starting dose of 50 mg/day
(76). The trial resulted in a RR of 11%, PFS of 12 weeks,
and OS of 23.4 weeks. These findings are comparable with
those of currently approved agents in this treatment setting.
The most common grade 3/4 nonhematologic AEs included
fatigue/asthenia (29%), pain/myalgia (17%), dyspnea (11%),
and nausea/vomiting (10%). The grade 3/4 hematologic AEs
included lymphopenia (25%), thrombocytopenia (5%), and
neutropenia (5%) (76). Notably, of the three patients in
the study who suffered hemorrhage-related deaths, two had
squamous NSCLC (both experienced pulmonary hemor-
rhage). In a separate, open-label phase II study, sunitinib
was administered continuously (without a 2-week break) at
a lower starting dose of 37.5 mg/day to 47 patients with ad-
vanced NSCLC as second- or third-line treatment (77). One
patientachievedaPR,and11patientsdemonstratedSD.Me-
dian PFS and OS were 2.7 months and 8.6 months, respec-
tively. The most frequently reported grade 3/4 AEs included
fatigue (17.0%), hypertension (8.5%), and dyspnea (6.4%).
In a phase I study, sunitinib was combined with cisplatin
and gemcitabine as first-line therapy in patients with ad-
vanced NSCLC (78). The combination resulted in a manage-
able toxicity profile and PRs were observed in five of 24 pa-
tients. A second phase I study evaluated the combination of
sunitinib and docetaxel in 50 patients with advanced solid
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Table 4. Overview of ongoing (actively recruiting) phase II and III trials of antiangiogenic TKIs in NSCLCa
Agent Trial Description Identifier Number
Sorafenib
Phase II trial of sorafenib in patients with advanced NSCLC after failure of EGFR-TKI. NCT00922584
Phase II trial of sorafenib in combination with erlotinib in patients with advanced NSCLC after failure of
chemotherapy.
NCT00801385
Phase II trial of sorafenib in patients with relapsed or refractory advanced NSCLC (nonsmokers or former light
smokers).
NCT00754923
Phase III trial of third- or fourth-line sorafenib versus placebo in patients with predominantly nonsquamous
NSCLC.
NCT00863746
Sunitinib
Phase II trial of first-line sunitinib in patients aged >70 years with advanced NSCLC. NCT00864721
Phase II trial of second-line sunitinib and/or pemetrexed in patients with advanced NSCLC. NCT00698815
Phase II trial of sunitinib in combination with cisplatin and docetaxel as salvage therapy in patients with
advanced NSCLC.
NCT01019798
Phase II trial of sunitinib as maintenance therapy in patients with advanced NSCLC previously treated with
combination chemotherapy.
NCT01210053
Phase III trial of sunitinib versus placebo as maintenance therapy in patients with advanced NSCLC previously
treated with combination chemotherapy.
NCT00693992
Cediranib
Phase III trial of first-line cediranib in combination with carboplatin and paclitaxel in patients with advanced
NSCLC (BR. 29).
NCT00795340
Phase II trial of second- or third-line cediranib in combination with pemetrexed in patients with advanced
NSCLC.
NCT00410904
Vandetanib
Phase II trial of first-line vandetanib in combination with carboplatin and paclitaxel in patients with advanced
NSCLC.
NCT00093392
BIBF 1120
Phase III trial of second-line BIBF 1120 in combination with docetaxel versus docetaxel alone in patients with
advanced NSCLC (LUME-Lung 1).
NCT00805194
Phase III trial of second-line BIBF 1120 in combination with pemetrexed versus pemetrexed alone in patients
with advanced nonsquamous NSCLC (LUME-Lung 2).
NCT00806819
Pazopanib
Phase II/III trial of adjuvant pazopanib versus placebo in patients with stage I surgically resected NSCLC. NCT00775307
Phase II trial of first-line pazopanib in combination with paclitaxel versus carboplatin in combination with
paclitaxel in patients with advanced NSCLC.
NCT00866528
Phase II trial of second-line pazopanib in combination with erlotinib versus erlotinib alone in patients with
advanced NSCLC.
NCT01027598
Phase II trial of third-line pazopanib in patients with advanced NSCLC. NCT01049776
Axitinib
Phase II trial of first-line axitinib in combination with cisplatin and gemcitabine in patients with squamous
NSCLC.
NCT00735904
aClinicalTrials.gov accessed on November 22, 2010.
Abbreviations. EGFR: epidermal growth factor receptor; NSCLC: non-small cell lung cancer; TKI: tyrosine kinase inhibitor.
tumors, including 18 patients with NSCLC (79). PR was ob-
served in three patients, SD was observed in 12 patients,
andAEsweremanageable.Ongoingclinicaltrialsarefurther
evaluating the benefits of adding sunitinib to standard ther-
apies and as maintenance after first-line therapy (Table 4).
Cediranib
Cediranib is a highly potent and selective inhibitor of the
VEGF pathway with activity against all three VEGFRs,
PDGFRs, and c-kit (80). In phase I studies, cediranib has
demonstratedantitumoractivityasasingleagentwithaman-
ageabletoxicityprofile.ThemostfrequentlyreportedAEsin-
cludediarrhea,fatigue,dysphonia,andhypertension(81,82).
Cediranib at doses of 20, 30, and 45 mg was evaluated in
a phase I study in combinationwith four chemotherapyregi-
mens (FOLFOX, irinotecan, docetaxel, and pemetrexed) in
4 6h e a v i l yp r e t r e a t e dp a t i e n t sw i t ha d v a n c e ds o l i dt u m o r s
( 8 3 ) .O f3 5p a t i e n t sw h ow e r ee v a l u a b l ef o rt o x i c i t y ,g r a d e
3/4 AEs observed across all four arms included fatigue, di-
arrhea, hand–foot syndrome, neutropenic fever, and hyper-
t e n s i o n( 8 3 ) .I na n o t h e rp h a s eIs t u d y( N= 15), cediranib
30 mg and 45 mg was combined with standard doses of cis-
platin/gemcitabine in patients with advanced NSCLC (84).
Thecombinationwasassociatedwithincreasedtoxicitycom-
pared with chemotherapy alone (84). All 12 of the evalu-
able patients showed some degree of initial tumor shrinkage
a n df o u ra c h i e v e dP R s( 8 4 ) .I na n o t h e rp h a s eIt r i a l( N=
20), once-daily cediranib 30 mg and 45 mg in combination
with carboplatin/paclitaxel administered every 3 weeks was
evaluated as first-line treatment in patients with advanced
NSCLC(85).Patientsreceivinganticoagulationwereeligible,
b u tp a t i e n t sw i t hah i s t o r yo fh e m o p t y s i so rb l e e d i n gw e r e
excluded. Adverse events included fatigue, myalgia, hyper-
tension,GItoxicities,andneutropenia(85).Progression-free
s u r v i v a lw a sr e p o r t e di nn i n ep a t i e n t s ,a n da l lb u to n ep a -
tientshowedsomeevidenceoftumorshrinkage;medianTTP
was7.6months(85).Antitumoractivitywasobservedatboth
dose levels, but with no indication of a dose effect (85).
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BR .24 is a randomized, double-blind, placebo-controlled
phase II/III trial of cediranib 30 mg in combination with
carboplatin/paclitaxel as first-line treatment in patients with
NSCLC (86). This trial was not continued into phase III as
there appeared to be excessive toxicity, although evidence of
clinical activity was observed (86, 87). BR.29 will compare
cediranib 20 mg in combination with carboplatin/paclitaxel
with chemotherapy alone as first-line treatment in patients
with NSCLC (Table 4).
An ongoing phase II trial is evaluating cediranib in com-
bination with pemetrexed for second- or third-line treat-
ment of advanced NSCLC (Table 3) (68). This study consists
of two cohorts: patients who have not received prior beva-
cizumab(cohortA)andpatientswhohavereceivedpriorbe-
vacizumab (cohort B). In a preliminary analysis of the first
31evaluablepatients,theconfirmedRRwas16%(10%inco-
hort A and 25% in cohort B) and the disease control rate was
71% (74% in cohort A and 67% in cohort B). The grade 3/4
nonhematologic AEs included fatigue (21%), diarrhea (9%),
anorexia (6%), hypertension (3%), cardiac ischemia (3%),
bronchopleuralfistula(3%),andesophagitis(3%).Thegrade
3/4 neutropenia was reported in 21% of patients and febrile
neutropenia occurred in 3% of patients (68).
Vandetanib
Vandetanib is a small-molecule inhibitor that blocks both
t h eV E G F Ra n dE G F Rp a t h w a y s ,a l t h o u g hi ti sm o r es p e -
cific for the VEGFR pathway (88, 89). It is also a potent in-
hibitorofRETreceptorTKactivity(72).Anumberofstudies
have evaluated vandetanib in combination with chemother-
apy (Table 3) (69–73). Response rates were increased in the
combination arms compared to chemotherapy-only arms. In
addition, most of these studies demonstrated a prolongation
in PFS, but no improvement in OS. In a double-blind ran-
domized, phase 3 trial (ZODIAC) the combination of van-
detanib and docetaxel was evaluated as a second-line treat-
mentinpatientswithadvancedNSCLC(N=1,391).Thead-
dition of vandetanib improved PFS (4.0 months in the Van-
detanib group vs. 3.2 months in the placebo group) but no
significant improvement in OS was reported (72). ZEIST, a
randomized phase III trial (N = 1,240) in patients with ad-
vanced,previouslytreatedNSCLC,demonstratedthatsingle-
agentvandetanibanderlotinibhadequivalentefficacybyPFS
(HR, 0.98; p = .721) and OS (HR, 1.01; p = .830), but that
vandetanib was associated with a higher incidence of toxic-
ity (90). Vandetanib is also being evaluated in the phase III
t r i a l( Z E P H Y R )i np a t i e n t sw i t ha d v a n c e dN S C L Cw h oh a v e
progressed after treatment with chemotherapy and an EGFR
TKI, but preliminary results indicate that the trial did not
reach its primary end point of OS (91). Regulatory submis-
sions for vandetanib in patients with NSCLC have also been
withdrawn (91).
BIBF1120
BIBF 1120 is a TKI targeting VEGFR1, VEGFR2, VEGFR3,
FGFR1, FGFR2, FGFR3, and PDGFR, with the potential
to inhibit proangiogenic signaling pathways in vascular en-
dothelialcells, pericytes, andsmooth-musclecells (92). BIBF
1120 was evaluated as a single agent in a phase II trial in 73
patients with advanced NSCLC who had received one to two
prior chemotherapeutic regimens (93). Patients were ran-
domly assigned to receive twice-daily BIBF 1120, 150 mg (N
= 37) or 250 mg (N = 36). Median PFS was 1.6 months in
the overall population (N = 73) and 2.9 months in patients
withanECOGperformancestatus(PS)0to1(N=57),while
median OS was 22 weeks in the overall population and 38
weeks in patients with PS 0 to 1. One PR was achieved, and
the SD rate was 48% for all patients and 59% in patients with
a PS of 0 to 1. The grade 3/4 toxicities included reversible
alanine aminotransferase (ALT) elevations (9.6%), diarrhea
(9.6%), nausea (8.2%), fatigue (5.5%), and vomiting (4.1%)
(93). BIBF 1120 was not associated with a high frequency of
hypertension,whichiscommonlyreportedwithotherVEGF
inhibitors (46, 93).
Results from phase I studies confirmed the feasibility
of combining BIBF 1120 with chemotherapy (94, 95). In a
phase I trial (N = 25), BIBF 1120 in combination with car-
boplatin/paclitaxel was evaluated in chemo-naive patients
with advanced NSCLC (94). The maximum tolerated dose
(MTD) of BIBF 1120 was 200 mg twice daily, and no clini-
cally relevant changes to carboplatin/paclitaxel pharmacoki-
neticparameterswereobserved(94).InanotherphaseIdose-
escalation study, BIBF 1120 plus pemetrexed (500 mg/m
2)
was administered to 26 patients with NSCLC who had re-
ceived prior first-line, platinum-based chemotherapy (95).
The MTD of BIBF 1120, in combination with standard-dose
p e m e t r e x e d ,w a s2 0 0m gt w i c ed a i l y ,w i t hn oc l i n i c a l l yr e l e -
vanteffectsofBIBF1120pharmacokineticsobservedincom-
binationwithpemetrexed(95).Duringthefirsttreatmentcy-
cle, dose-limiting toxicities (DLTs) (all grade 3) occurred in
seven patients for all doses and included transaminase ele-
vations, fatigue, confusion, anorexia, and GI disorders (95).
Among the 26 evaluable patients, one patient achieved a CR
a n d1 3( 5 0 % )p a t i e n t sh a dS D .B a s e do nt h e s ed a t a ,t w or a n -
domized phase III studies are under way to evaluate BIBF
1120 in combination with docetaxel or pemetrexed for pa-
tientswithadvancedNSCLCafterfailureoffirst-linetherapy
(Table 4).
Pazopanib
Pazopanib is a multitargeted TKI that blocks VEGFR1,
VEGFR2,VEGFR3,PDGFR,andc-kit(96).Preclinicalstud-
iesindicatethatpazopanibiseffectiveininhibitingangiogen-
esis(97).Pazopanibhasbeenusedasneoadjuvantmonother-
apy in patients with early-stage NSCLC (98). Of a total of 35
patients, three achieved a PR. The grade 3 toxicities were ob-
served in five patients and included ALT elevations, hyper-
tension, dyspnea, pneumonia, urinary tract infection, rash,
increase in blood potassium, and lymphopenia. One patient
experiencedgrade4bilateralpulmonaryemboli11daysafter
surgery (98). In a separate exploratory analysis of cytokines
and angiogenic factors (C/AFs) in the serum of patients with
early-stageNSCLCwhoreceivedpreoperativetreatmentwith
pazopanib, significant changes in eight C/AFs were reported
(99). In particular, plasma levels of VEGFR2 (p < .0001) and
placental growth factor (PIGF; p < .0001) were significantly
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decreased after pazopanib treatment. There was also a corre-
lation between serum levels of VEGFR2 and tumor shrink-
age (p < .05), suggesting its potential for use as a predictive
marker of response (99). The efficacy and tolerability of pa-
zopanib in advanced NSCLC, either alone or in combination
with chemotherapy, is being evaluated in numerous clinical
trials (Table 4).
Axitinib
Axitinib is a potent small-molecule TKI of VEGFR1,
VEGFR2, VEGFR3, PDGR, and c-kit (100). In a phase I
trial in 36 patients with advanced solid tumors, single-agent
axitinib demonstrated antitumor activity in multiple tumor
types, including NSCLC (101). The most common toxicities
of any grade were hypertension (61%), fatigue (28%), nausea
(19%),anddiarrhea(17%)(101).Basedonthesedata,aphase
II study was conducted in 32 patients with advanced NSCLC
(102).Ninepatientshadnotreceivedpriorchemotherapyfor
metastaticdisease and 23 patientsreceived≥1p rio rr egim en
(102).Responseratewas9%andmedianPFSwas4.9months
in the overall study population and 9.2 months in treatment-
naive patients. Median OS was 14.8 months in the overall
populationand14.8monthsinpatientswhoreceivedaxitinib
as first-line therapy. One-year survival rates were 57% and
78%, respectively. Of the grade 1 or 2 AEs that occurred in
at least 15% of patients, those that also occurred at grade 3
severity included fatigue, hypertension, diarrhea, and vomit-
ing (102).
Axitinib was combined with standard paclitaxel/
carboplatin and gemcitabine/cisplatin chemotherapy in a
phase I trial of 47 patients with NSCLC and other solid
tumors (103). Response rate in the paclitaxel/carboplatin
cohort was 29%, and in the gemcitabine/cisplatin cohort RR
was 26% (103). The dose-limiting toxicities included fatigue,
proteinuria, and rashes (103). A subcohort analysis of pa-
tients with squamous cell histology showed that axitinib plus
paclitaxel/carboplatinwaswelltolerated,withnoevidenceof
grade ≥3 hemoptysis (103). Trials with single-agent axitinib
and combination therapy with axitinib in advanced NSCLC
are ongoing (Tables 3 and 4).
CONCLUSIONS
The availability of treatment options for patients with ad-
vanced NSCLC has expanded. As seen in the E4599 trial of
bevacizumab, therapy aimed at blocking angiogenesis can be
effective when combined with standard doublet chemother-
apyinpatientswithNSCLC.Whilealargenumberofpatients
were initially excluded from bevacizumab treatment because
of safety concerns, some of these patients are now eligible,
including patients with brain metastases and those receiv-
ing anticoagulation therapy. Patients with squamous histol-
ogy remain ineligible.Subgroupanalyses have shown limited
efficacy and increased toxicity in the elderly, in whom beva-
cizumab should be used with caution.
Several multitargeted, antiangiogenic TKIs in clinical de-
velopment for NSCLC have shown feasibility for combina-
tion with standard chemotherapy. The clinical advantages of
this class of drugs are their oral administration and activity
against multiple targets. However, improved OS in combina-
tion with chemotherapy has yet to be demonstrated in phase
III trials. To date, toxicity profiles with these agents seem ac-
ceptable.LargephaseIIItrialswilldeterminetheroleofthese
agents in the treatment of patients with advanced NSCLC.
How do we personalize treatment strategies with antian-
giogenic agents to achieve maximal efficacy with minimal
toxicity? The identification of effective biomarkers will be
critical. Several biomarkers have already been evaluated (al-
though not validated) and may be predictive of treatment
benefit. The development of hypertension may also be a
surrogate marker of efficacy in patients treated with beva-
cizumab. Molecular markers and genetic mapping will be
important for individualizing treatment regimens, predict-
ingwhichpatientsmightbenefitfromspecificregimens,and
evaluating the efficacy of specific antiangiogenic therapies.
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